1. Home
  2. GENK vs KPRX Comparison

GENK vs KPRX Comparison

Compare GENK & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

N/A

Current Price

$0.92

Market Cap

9.1M

ML Signal

N/A

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

N/A

Current Price

$0.93

Market Cap

10.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GENK
KPRX
Founded
2011
1998
Country
United States
United States
Employees
2700
N/A
Industry
Restaurants
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
10.6M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
GENK
KPRX
Price
$0.92
$0.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 143.3K
65.8K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 62.50
N/A
EPS
★ N/A
N/A
Revenue
★ $208,380,000.00
N/A
Revenue This Year
$1.16
N/A
Revenue Next Year
$5.86
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.12
N/A
52 Week Low
$0.92
$0.93
52 Week High
$2.82
$2.91

Technical Indicators

Market Signals
Indicator
GENK
KPRX
Relative Strength Index (RSI) 30.27 16.96
Support Level N/A N/A
Resistance Level $2.25 $2.66
Average True Range (ATR) 0.15 0.16
MACD -0.04 -0.05
Stochastic Oscillator 4.74 0.42

Price Performance

Historical Comparison
GENK
KPRX

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: